Use of 5-α-reductase inhibitors for prostate cancer chemoprevention: American society of clinical oncology/American Urological Association 2008 clinical practice guideline summary

Barnett S. Kramer, Karen L. Hagerty, Stewart Justman, Mark R. Somerfield, Peter C. Albertsen, William J. Blot, H. Ballentine Carter, Joseph P. Costantino, Jonathan I. Epstein, Paul Godley, Russell P. Harris, Timothy J. Wilt, Janet Wittes, Robin Zon, Paul Schellhammer

Research output: Contribution to journalShort survey

Original languageEnglish (US)
Pages (from-to)127-129
Number of pages3
JournalJournal of oncology practice
Volume5
Issue number3
DOIs
StatePublished - May 2009
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)
  • Health Policy

Cite this

Kramer, B. S., Hagerty, K. L., Justman, S., Somerfield, M. R., Albertsen, P. C., Blot, W. J., Carter, H. B., Costantino, J. P., Epstein, J. I., Godley, P., Harris, R. P., Wilt, T. J., Wittes, J., Zon, R., & Schellhammer, P. (2009). Use of 5-α-reductase inhibitors for prostate cancer chemoprevention: American society of clinical oncology/American Urological Association 2008 clinical practice guideline summary. Journal of oncology practice, 5(3), 127-129. https://doi.org/10.1200/JOP.0938503